532 related articles for article (PubMed ID: 25111682)
61. Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
Mori K; Ando K; Heymann D; Rédini F
Histol Histopathol; 2009 Feb; 24(2):235-42. PubMed ID: 19085839
[TBL] [Abstract][Full Text] [Related]
62. Effects of Wenyangbushen formula on the expression of VEGF, OPG, RANK and RANKL in rabbits with steroid-induced femoral head avascular necrosis.
Song HM; Wei YC; Li N; Wu B; Xie N; Zhang KM; Wang SZ; Wang HM
Mol Med Rep; 2015 Dec; 12(6):8155-61. PubMed ID: 26496816
[TBL] [Abstract][Full Text] [Related]
63. Immunohistochemical localization of RANK, RANKL and OPG in healthy and arthritic canine elbow joints.
Spahni AI; Schawalder P; Rothen B; Bosshardt DD; Lang N; Stoffel MH
Vet Surg; 2009 Aug; 38(6):780-6. PubMed ID: 19674422
[TBL] [Abstract][Full Text] [Related]
64. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S; Phillips JS; Sayers J; Croucher PI
J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
[TBL] [Abstract][Full Text] [Related]
65. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
[TBL] [Abstract][Full Text] [Related]
66. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin expression in chronic apical periodontitis: possible association with inflammatory cells.
Fan R; Sun B; Zhang CF; Lü YL; Xuan W; Wang QQ; Yin XZ
Chin Med J (Engl); 2011 Jul; 124(14):2162-6. PubMed ID: 21933620
[TBL] [Abstract][Full Text] [Related]
67. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
[TBL] [Abstract][Full Text] [Related]
68. Serum osteoprotegerin levels and mammographic density among high-risk women.
Moran O; Zaman T; Eisen A; Demsky R; Blackmore K; Knight JA; Elser C; Ginsburg O; Zbuk K; Yaffe M; Narod SA; Salmena L; Kotsopoulos J
Cancer Causes Control; 2018 Jun; 29(6):507-517. PubMed ID: 29679262
[TBL] [Abstract][Full Text] [Related]
69. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
[TBL] [Abstract][Full Text] [Related]
70. Oxidized Titanium Implants Enhance Osseointegration via Mechanisms Involving RANK/RANKL/OPG Regulation.
Lennerås M; Palmquist A; Norlindh B; Emanuelsson L; Thomsen P; Omar O
Clin Implant Dent Relat Res; 2015 Oct; 17 Suppl 2():e486-500. PubMed ID: 25536123
[TBL] [Abstract][Full Text] [Related]
71. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
[TBL] [Abstract][Full Text] [Related]
72. Effect of hydrogen sulphide on the expression of osteoprotegerin and receptor activator of NF-κB ligand in human periodontal ligament cells induced by tension-force stimulation.
Liao C; Hua Y
Arch Oral Biol; 2013 Dec; 58(12):1784-90. PubMed ID: 24200305
[TBL] [Abstract][Full Text] [Related]
73. The role of RANK/RANKL/OPG signalling pathways in osteoclastogenesis in odontogenic keratocysts, radicular cysts, and ameloblastomas.
Tekkesin MS; Mutlu S; Olgac V
Head Neck Pathol; 2011 Sep; 5(3):248-53. PubMed ID: 21643971
[TBL] [Abstract][Full Text] [Related]
74. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.
Peng X; Guo W; Ren T; Lou Z; Lu X; Zhang S; Lu Q; Sun Y
PLoS One; 2013; 8(3):e58361. PubMed ID: 23516466
[TBL] [Abstract][Full Text] [Related]
75. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
76. Key roles of the OPG-RANK-RANKL system in bone oncology.
Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
[TBL] [Abstract][Full Text] [Related]
77. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
78. OPG/RANK/RANKL axis in atrial fibrillation.
Xi L; Cao H; Chen Y
Cardiology; 2013; 125(3):174-5. PubMed ID: 23752030
[No Abstract] [Full Text] [Related]
79. Genetic variations in the genes encoding receptor activator nuclear factor κ B (RANK), receptor activator nuclear factor κ B ligand (RANKL) and osteoprotegerin (OPG) in patients with psoriasis and psoriatic arthritis: a case-control study.
Assmann G; Pfoehler C; Simon P; Pfreundschuh M; Tilgen W; Wieczorek S
J Dermatol; 2011 Jun; 38(6):519-23. PubMed ID: 21352301
[TBL] [Abstract][Full Text] [Related]
80. Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.
Poornima IG; Mackey RH; Buhari AM; Cauley JA; Matthews KA; Kuller LH
Menopause; 2014 Jul; 21(7):702-10. PubMed ID: 24473535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
